Machine learning-, rule- and pharmacophore-based classification on the inhibition of P-glycoprotein and NorA

References

• M. Pesic, J. Bankovic, and N. Tanic, Targeted anti-cancer therapy, acquiring and overcoming multi-drug resistance, in Frontiers in Anti-Cancer Drug Discovery, Atta-ur-Rahman and M. I. Choudhary, eds., Bentham Science, Sharjah, 2014, pp. 109–150.
   Google Scholar
• H. Nikaido, Multidrug resistance in bacteria, Annu. Rev. Biochem. 78 (2009), pp. 119–146.
   PubMed Web of Science ®Google Scholar
• H. Nikaido and J.M. Pages, Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria, FEMS Microbiol. Rev. 36 (2012), pp. 340–363.
   PubMed Web of Science ®Google Scholar
• C. Avendaño and J.C. Menéndez, Drugs that modulate resistance to antitumor agents, in Medicinal Chemistry of Anticancer Drugs, C. Avendaño and J.C. Menéndez, eds., Elsevier, Amsterdam, 2008, pp. 387–416.
   Google Scholar
• B. Marquez, Bacterial efflux systems and efflux pumps inhibitors, Biochimie 87 (2005), pp. 1137–1147.
   PubMed Web of Science ®Google Scholar
• P. Ughachukwu and P. Unekwe, Efflux pump-mediated resistance in chemotherapy, Ann. Med. Health Sci. Res. 2 (2012), pp. 191–198.
   PubMedGoogle Scholar
• J. Sun, Z. Deng, and A. Yan, Bacterial multidrug efflux pumps: Mechanisms, physiology and pharmacological exploitations, Biochem. Biophys. Res. Commun. 453 (2014), pp. 254–267.
   PubMed Web of Science ®Google Scholar
• K. Dano, Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells, Biochim. Biophys. Acta 323 (1973), pp. 466–483.
   PubMed Web of Science ®Google Scholar
• C. Cordon-Cardo, J.P. O'Brien, J. Boccia, D. Casals, J.R. Bertino, and M.R. Melamed, Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues, J. Histochem. Cytochem. 38 (1990), pp. 1277–1287.
   PubMed Web of Science ®Google Scholar
• A.W. Abu-Qare, E. Elmasry, and M.B. Abou-Donia, A role for P-glycoprotein in environmental toxicology, J. Toxicol. Environ. Health B Crit. Rev. 6 (2003), pp. 279–288.
   PubMed Web of Science ®Google Scholar
• G. Lehne, P-glycoprotein as a drug target in the treatment of multidrug resistant cancer, Curr. Drug Targets 1 (2000), pp. 85–99.
   PubMed Web of Science ®Google Scholar
• J.H. Lin and M. Yamazaki, Role of P-glycoprotein in pharmacokinetics: Clinical implications, Clin. Pharmacokinet. 42 (2003), pp. 59–98.
   PubMed Web of Science ®Google Scholar
• M.F. Fromm, Importance of P-glycoprotein for drug disposition in humans, Eur. J. Clin. Invest. 33(Suppl 2) (2003), pp. 6–9.
   PubMedGoogle Scholar
• S. Eberl, B. Renner, A. Neubert, M. Reisig, I. Bachmakov, J. Konig, F. Dorje, T.E. Murdter, A. Ackermann, H. Dormann, K.G. Gassmann, E.G. Hahn, S. Zierhut, K. Brune, and M.F. Fromm, Role of p-glycoprotein inhibition for drug interactions: Evidence from in vitro and pharmacoepidemiological studies, Clin. Pharmacokinet. 46 (2007), pp. 1039–1049.
   PubMed Web of Science ®Google Scholar
• C. Kourtesi, A.R. Ball, Y.Y. Huang, S.M. Jachak, D.M. Vera, P. Khondkar, S. Gibbons, M.R. Hamblin, and G.P. Tegos, Microbial efflux systems and inhibitors: Approaches to drug discovery and the challenge of clinical implementation, Open Microbiol. J. 7 (2013), pp. 34–52.
   PubMedGoogle Scholar
• G.W. Kaatz and S.M. Seo, Mechanisms of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus, Antimicrob. Agents Chemother. 41 (1997), pp. 2733–2737.
   PubMed Web of Science ®Google Scholar
• S.S. Costa, M. Viveiros, L. Amaral, and I. Couto, Multidrug efflux pumps in Staphylococcus aureus: An update, Open Microbiol. J. 7 (2013), pp. 59–71.
   PubMedGoogle Scholar
• M. Tanaka, T. Wang, Y. Onodera, Y. Uchida, and K. Sato, Mechanism of quinolone resistance in Staphylococcus aureus, J. Infect. Chemother. 6 (2000), pp. 131–139.
   PubMedGoogle Scholar
• C. Kosmidis, B.D. Schindler, P.L. Jacinto, D. Patel, K. Bains, S.M. Seo, and G.W. Kaatz, Expression of multidrug resistance efflux pump genes in clinical and environmental isolates of Staphylococcus aureus, Int. J. Antimicrob. Agents 40 (2012), pp. 204–209.
   PubMed Web of Science ®Google Scholar
• J.R. Aeschlimann, L.D. Dresser, G.W. Kaatz, and M.J. Rybak, Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus, Antimicrob. Agents Chemother. 43 (1999), pp. 335–340.
   PubMed Web of Science ®Google Scholar
• J. Handzlik, A. Matys, and K. Kieć-Kononowicz, Recent advances in multi-drug resistance (MDR) efflux pump inhibitors of gram-positive bacteria S. aureus, Antibiotics 2 (2013), pp. 28–45.
   Google Scholar
• K.M.R. Srivalli and P.K. Lakshmi, Overview of P-glycoprotein inhibitors: A rational outlook, Braz. J. Pharm. Sci. 48 (2012), pp. 353–367.
   Web of Science ®Google Scholar
• G.W. Kaatz, Inhibition of bacterial efflux pumps: A new strategy to combat increasing antimicrobial agent resistance, Expert Opin. Emerg. Drugs 7 (2002), pp. 223–233.
   PubMedGoogle Scholar
• T. Ozben, Mechanisms and strategies to overcome multiple drug resistance in cancer, FEBS Lett. 580 (2006), pp. 2903–2909.
   PubMed Web of Science ®Google Scholar
• L. Zhang and S. Ma, Efflux pump inhibitors: A strategy to combat P-glycoprotein and the NorA multidrug resistance pump, ChemMedChem 5 (2010), pp. 811–822.
   PubMed Web of Science ®Google Scholar
• K.M. Thai, T.N. Do, T.V.P. Nguyen, D.K.T. Nguyen, and T.D. Tran, QSAR studies on bacterial efflux pump inhibitors, in Quantitative Structure-Activity Relationships in Drug Design, Predictive Toxicology, and Risk Assessment, R. Kunal, ed., IGI Global, Hershey, PA, USA, 2015, pp. 238–268.
   Google Scholar
• A. Palmeira, E. Sousa, M.H. Vasconcelos, and M.M. Pinto, Three decades of P-gp inhibitors: Skimming through several generations and scaffolds, Curr. Med. Chem. 19 (2012), pp. 1946–2025.
   PubMed Web of Science ®Google Scholar
• G. Szakacs, J.K. Paterson, J.A. Ludwig, C. Booth-Genthe, and M.M. Gottesman, Targeting multidrug resistance in cancer, Nat. Rev. Drug Discov. 5 (2006), pp. 219–234.
   PubMed Web of Science ®Google Scholar
• A. Saneja, V. Khare, N. Alam, R.D. Dubey, and P.N. Gupta, Advances in P-glycoprotein-based approaches for delivering anticancer drugs: Pharmacokinetic perspective and clinical relevance, Expert Opin. Drug Deliv. 11 (2014), pp. 121–138.
   PubMed Web of Science ®Google Scholar
• A. Saneja, R.D. Dubey, N. Alam, V. Khare, and P.N. Gupta, Co-formulation of P-glycoprotein substrate and inhibitor in nanocarriers: An emerging strategy for cancer chemotherapy, Curr. Cancer Drug Targets 14 (2014), pp. 419–433.
   PubMed Web of Science ®Google Scholar
• R. Callaghan, F. Luk, and M. Bebawy, Inhibition of the multidrug resistance P-glycoprotein: Time for a change of strategy?, Drug Metab. Dispos. 42 (2014), pp. 623–631.
   PubMed Web of Science ®Google Scholar
• R.K. Oldham, W.K. Reid, H.D. Preisler, and D. Barnett, A phase I and pharmacokinetic study of CBT-1 as a multidrug resistance modulator in the treatment of patients with advanced cancer, Cancer Biother. Radiopharm. 13 (1998), pp. 71–80.
   PubMed Web of Science ®Google Scholar
• R.K. Oldham, W.K. Reid, and D. Barnett, Phase I study of CBT-1 and taxol in patients with taxol resistant cancers, Cancer Biother. Radiopharm. 15 (2000), pp. 153–159.
   PubMed Web of Science ®Google Scholar
• R.J. Kelly, R.W. Robey, C.C. Chen, D. Draper, V. Luchenko, D. Barnett, R.K. Oldham, Z. Caluag, A.R. Frye, S.M. Steinberg, T. Fojo, and S.E. Bates, A pharmacodynamic study of the P-glycoprotein antagonist CBT-1(R) in combination with paclitaxel in solid tumors, Oncologist 17 (2012), p. 512.
   PubMed Web of Science ®Google Scholar
• V. Poongavanam, N. Haider, and G.F. Ecker, Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors, Bioorg. Med. Chem. 20 (2012), pp. 5388–5395.
   PubMed Web of Science ®Google Scholar
• L. Chen, Y. Li, Q. Zhao, H. Peng, and T. Hou, ADME evaluation in drug discovery. 10. Predictions of P-glycoprotein inhibitors using recursive partitioning and naive Bayesian classification techniques, Mol. Pharm. 8 (2011), pp. 889–900.
   PubMed Web of Science ®Google Scholar
• MOE 2008.10. Chemical Computing Group Inc., 1010 Sherbrooke St. W, Suite 910, Montreal, Quebec, Canada H3A 2R7; software available at http://www.chemcomp.com.
   Google Scholar
• Z. Parveen, G. Brunhofer, I. Jabeen, T. Erker, P. Chiba, and G.F. Ecker, Synthesis, biological evaluation and 3D-QSAR studies of new chalcone derivatives as inhibitors of human P-glycoprotein, Bioorg. Med. Chem. 22 (2014), pp. 2311–2319.
   PubMed Web of Science ®Google Scholar
• J. Rautio, J.E. Humphreys, L.O. Webster, A. Balakrishnan, J.P. Keogh, J.R. Kunta, C.J. Serabjit-Singh, and J.W. Polli, In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: A recommendation for probe substrates, Drug Metab. Dispos. 34 (2006), pp. 786–792.
   PubMed Web of Science ®Google Scholar
• F. Broccatelli, E. Carosati, A. Neri, M. Frosini, L. Goracci, T.I. Oprea, and G. Cruciani, A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields, J. Med. Chem. 54 (2011), pp. 1740–1751.
   PubMed Web of Science ®Google Scholar
• J.P. Brincat, F. Broccatelli, S. Sabatini, M. Frosini, A. Neri, G.W. Kaatz, G. Cruciani, and E. Carosati, Ligand promiscuity between the efflux pumps human P-glycoprotein and S. aureus NorA, ACS Med. Chem. Lett. 3 (2012), pp. 248–251.
   PubMed Web of Science ®Google Scholar
• P. Joshi, S. Singh, A. Wani, S. Sharma, S.K. Jain, B. Singh, B.D. Gupta, N.K. Satti, S. Koul, I.A. Khan, A. Kumar, S.B. Bharate, and R.A. Vishwakarma, Osthol and curcumin as inhibitors of human Pgp and multidrug efflux pumps of Staphylococcus aureus: Reversing the resistance against frontline antibacterial drugs, MedChemComm 5 (2014), pp. 1540–1547.
   Web of Science ®Google Scholar
• F.J. Schmitz, A.C. Fluit, M. Luckefahr, B. Engler, B. Hofmann, J. Verhoef, H.P. Heinz, U. Hadding, and M.E. Jones, The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus, J. Antimicrob. Chemother. 42 (1998), pp. 807–810.
   PubMed Web of Science ®Google Scholar
• I.A. Khan, Z.M. Mirza, A. Kumar, V. Verma, and G.N. Qazi, Piperine, a phytochemical potentiator of ciprofloxacin against Staphylococcus aureus, Antimicrob. Agents Chemother. 50 (2006), pp. 810–812.
   PubMed Web of Science ®Google Scholar
• N.P. Kalia, P. Mahajan, R. Mehra, A. Nargotra, J.P. Sharma, S. Koul, and I.A. Khan, Capsaicin, a novel inhibitor of the NorA efflux pump, reduces the intracellular invasion of Staphylococcus aureus, J. Antimicrob. Chemother. 67 (2012), pp. 2401–2408.
   PubMed Web of Science ®Google Scholar
• E.Y. Ng, M. Trucksis, and D.C. Hooper, Quinolone resistance mediated by norA: Physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome, Antimicrob. Agents Chemother. 38 (1994), pp. 1345–1355.
   PubMed Web of Science ®Google Scholar
• I. Leitner, J. Nemeth, T. Feurstein, A. Abrahim, P. Matzneller, H. Lagler, T. Erker, O. Langer, and M. Zeitlinger, The third-generation P-glycoprotein inhibitor tariquidar may overcome bacterial multidrug resistance by increasing intracellular drug concentration, J. Antimicrob. Chemother. 66 (2011), pp. 834–839.
   PubMed Web of Science ®Google Scholar
• S. Gibbons, M. Oluwatuyi, and G.W. Kaatz, A novel inhibitor of multidrug efflux pumps in Staphylococcus aureus, J. Antimicrob. Chemother. 51 (2003), pp. 13–17.
   PubMed Web of Science ®Google Scholar
• S. Mullin, N. Mani, and T.H. Grossman, Inhibition of antibiotic efflux in bacteria by the novel multidrug resistance inhibitors biricodar (VX-710) and timcodar (VX-853), Antimicrob. Agents Chemother. 48 (2004), pp. 4171–4176.
   PubMed Web of Science ®Google Scholar
• A. Kumar, I.A. Khan, S. Koul, J.L. Koul, S.C. Taneja, I. Ali, F. Ali, S. Sharma, Z.M. Mirza, M. Kumar, P.L. Sangwan, P. Gupta, N. Thota, and G.N. Qazi, Novel structural analogues of piperine as inhibitors of the NorA efflux pump of Staphylococcus aureus, J. Antimicrob. Chemother. 61 (2008), pp. 1270–1276.
   PubMed Web of Science ®Google Scholar
• D. Dickens, A. Owen, A. Alfirevic, and M. Pirmohamed, Determination of the inhibitory potencies of p-glycoprotein inhibitors by transcellular permeability of Caco-2 cells, British Pharmacological Society Winter Meeting, 2009. Available at http://pa2online.org/abstracts/Vol7Issue4abst092P.pdf.
   Google Scholar
• T.-D. Ngo, T.-D. Tran, M.-T. Le, and K.-M. Thai, Computational predictive models for P-glycoprotein inhibition of in-house chalcone derivatives and DrugBank compounds, Mol. Divers. (2016), pp. 1–17. in press doi: http://dx.doi.org/10.1007/s11030-016-9688-5
   PubMedGoogle Scholar
• D.S. Wishart, C. Knox, A.C. Guo, S. Shrivastava, M. Hassanali, P. Stothard, Z. Chang, and J. Woolsey, DrugBank: A comprehensive resource for in silico drug discovery and exploration, Nucleic Acids Res. 34 (2006), pp. D668–D672.
   PubMed Web of Science ®Google Scholar
• D.S. Wishart, C. Knox, A.C. Guo, D. Cheng, S. Shrivastava, D. Tzur, B. Gautam, and M. Hassanali, DrugBank: A knowledgebase for drugs, drug actions and drug targets, Nucleic Acids Res. 36 (2008), pp. D901–D906.
   PubMed Web of Science ®Google Scholar
• C. Knox, V. Law, T. Jewison, P. Liu, S. Ly, A. Frolkis, A. Pon, K. Banco, C. Mak, V. Neveu, Y. Djoumbou, R. Eisner, A.C. Guo, and D.S. Wishart, DrugBank 3.0: A comprehensive resource for 'omics' research on drugs, Nucleic Acids Res. 39 (2011), pp. D1035–D1041.
   PubMed Web of Science ®Google Scholar
• V. Law, C. Knox, Y. Djoumbou, T. Jewison, A.C. Guo, Y. Liu, A. Maciejewski, D. Arndt, M. Wilson, V. Neveu, A. Tang, G. Gabriel, C. Ly, S. Adamjee, Z.T. Dame, B. Han, Y. Zhou, and D.S. Wishart, DrugBank 4.0: Shedding new light on drug metabolism, Nucleic Acids Res. 42 (2014), pp. D1091–D1097.
   PubMed Web of Science ®Google Scholar
• ChemBioDrawUltra 12.0. PerkinElmer, CambridgeSoft; software available at http://www.cambridgesoft.com.
   Google Scholar
• J. Zhang and J. Huan, Comparison of chemical descriptors for protein-chemical interaction prediction, Int. J. Comput. Biosci. 1 (2010), pp. 13–21.
   Google Scholar
• C.W. Yap, PaDEL-descriptor: An open source software to calculate molecular descriptors and fingerprints, J. Comput. Chem. 32 (2011), pp. 1466–1474.
   PubMed Web of Science ®Google Scholar
• M.A. Demel, A.G.K. Janecek, K.M. Thai, G.F. Ecker, and W.N. Gansterer, Predictive QSAR models for polyspecific drug targets: The importance of feature selection, Curr. Comput. Aided Drug Des. 4 (2008), pp. 91–110.
   Web of Science ®Google Scholar
• RapidMiner 5.3.008. Rapid-I and contributors, Stockumer Str. 475, 44227 Dortmund, Germany; software available at http://rapidminer.com.
   Google Scholar
• M. Hall, E. Frank, G. Holmes, B. Pfahringer, P. Reutemann, and I.H. Witten, The WEKA data mining software: An update, SIGKDD Explor. Newsl. 11 (2009), pp. 10–18.
   Google Scholar
• J. Jaworska, N. Nikolova-Jeliazkova, and T. Aldenberg, QSAR applicabilty domain estimation by projection of the training set descriptor space: A review, Altern. Lab. Anim. 33 (2005), pp. 445–459.
   PubMed Web of Science ®Google Scholar
• OECD, Guidance Document on the Validation of (Quantitative) Structure-Activity Relationship [(Q)SAR] Models, OECD Series on Testing and Assessment Vol. 69, OECD Publishing, Paris, 2014.
   Google Scholar
• T.I. Netzeva, A. Worth, T. Aldenberg, R. Benigni, M.T. Cronin, P. Gramatica, J.S. Jaworska, S. Kahn, G. Klopman, C.A. Marchant, G. Myatt, N. Nikolova-Jeliazkova, G.Y. Patlewicz, R. Perkins, D. Roberts, T. Schultz, D.W. Stanton, J.J. van de Sandt, W. Tong, G. Veith, and C. Yang, Current status of methods for defining the applicability domain of (quantitative) structure-activity relationships. The report and recommendations of ECVAM Workshop 52, Altern. Lab. Anim. 33 (2005), pp. 155–173.
   PubMed Web of Science ®Google Scholar
• K. Roy, S. Kar, and P. Ambure, On a simple approach for determining applicability domain of QSAR models, Chemometr. Intell. Lab. 145 (2015), pp. 22–29.
   Web of Science ®Google Scholar
• K. Roy and S. Kar, Importance of applicability domain of QSAR Models, in Quantitative Structure-Activity Relationships in Drug Design, Predictive Toxicology, and Risk Assessment, R. Kunal, ed., IGI Global, Hershey, PA, USA, 2015, pp. 180–211.
   Google Scholar
• D.A. Dobchev, G.G. Pillai, and M. Karelson, In silico machine learning methods in drug development, Curr. Top. Med. Chem. 14 (2014), pp. 1913–1922.
   PubMed Web of Science ®Google Scholar
• Clementine 12.0. SPSS Inc., 233 South Wacker Drive, 11th Floor, Chicago, IL 60606-6307, USA; software available at http://www.spss.com.
   Google Scholar
• I.H. Witten, E. Frank, and M.A. Hall, Data Mining: Practical Machine Learning Tools and Techniques, 3rd ed., Morgan Kaufmann Series in Data Management Systems Vol. Morgan Kaufmann, Burlington, MA, 2011.
   Google Scholar
• D.E. Rumelhart, G.E. Hinton, and J.L. McClelland, A general framework for parallel distributed processing, in Parallel distributed processing: Explorations in the microstructure of cognition, Vol. 1, E.R. David, L.M. James, and C.P.R. Group, eds., MIT Press, Cambridge, MA, 1986, pp. 45–76.
   Google Scholar
• R. Pandya and J. Pandya, C5.0 algorithm to improved decision tree with feature selection and reduced error pruning, Int. J. Comput. Appl. 117 (2015), pp. 18–21.
   Google Scholar
• W.J. Youden, Index for rating diagnostic tests, Cancer 3 (1950), pp. 32–35.
   PubMed Web of Science ®Google Scholar
• O.F. Güner and D.R. Henry, Metric for analyzing hit lists and pharmacophores, in Pharmacophore perception, development, and use in drug design, O. F. Güner, ed., 2000, pp. 195-211.
   Google Scholar
• K.M. Thai and G.F. Ecker, Classification models for HERG inhibitors by counter-propagation neural networks, Chem. Biol. Drug Des. 72 (2008), pp. 279–289.
   PubMed Web of Science ®Google Scholar
• P. Gramatica, Principles of QSAR models validation: Internal and external, QSAR Comb. Sci. 26 (2007), pp. 694–701.
   Google Scholar
• S. Ounpraseuth, S.Y. Lensing, H.J. Spencer, and R.L. Kodell, Estimating misclassification error: A closer look at cross-validation based methods, BMC Res. Notes 5 (2012), p. 656.
   PubMedGoogle Scholar
• P. Pratim Roy, S. Paul, I. Mitra, and K. Roy, On Two novel parameters for validation of predictive QSAR models, Molecules 14 (2009), pp. 1660–1701.
   PubMed Web of Science ®Google Scholar
• SPSS 20.0. IBM Corp., 1 New Orchard Road, Armonk, New York 10504-1722, United States; software available at http://www.ibm.com.
   Google Scholar
• B. Everitt, Multidimensional scaling and correspondence analysis, in An R and S-PLUS® Companion to Multivariate Analysis, Springer, London, 2005, pp. 91–114.
   Google Scholar
• C.G. Wermuth, C.R. Ganellin, P. Lindberg, and L.A. Mitscher, Glossary of terms used in medicinal chemistry (IUPAC recommendations 1998), Pure Appl. Chem. 70 (1998), pp. 1129–1143.
   Web of Science ®Google Scholar
• T. Langer, Pharmacophores in drug research, Mol. Inform. 29 (2010), pp. 470–475.
   PubMed Web of Science ®Google Scholar
• M. Löwer and E. Proschak, Structure-based pharmacophores for virtual screening, Mol. Inform. 30 (2011), pp. 398–404.
   PubMed Web of Science ®Google Scholar
• K.M. Thai, T.D. Ngo, T.D. Tran, and M.T. Le, Pharmacophore modeling for antitargets, Curr. Top. Med. Chem. 13 (2013), pp. 1002–1014.
   PubMed Web of Science ®Google Scholar
• A. Palmeira, E. Sousa, M.H. Vasconcelos, M. Pinto, and M.X. Fernandes, Structure and ligand-based design of P-glycoprotein inhibitors: A historical perspective, Curr. Pharm. Des. 18 (2012), pp. 4197–4214.
   PubMed Web of Science ®Google Scholar
• E. Dolghih, C. Bryant, A.R. Renslo, and M.P. Jacobson, Predicting binding to p-glycoprotein by flexible receptor docking, PLoS Comput. Biol. 7 (2011), p. e1002083.
   PubMed Web of Science ®Google Scholar
• L. Chen, Y. Li, H. Yu, L. Zhang, and T. Hou, Computational models for predicting substrates or inhibitors of P-glycoprotein, Drug Discov. Today 17 (2012), pp. 343–351.
   PubMed Web of Science ®Google Scholar
• S. Shityakov and C. Förster, In silico structure-based screening of versatile P-glycoprotein inhibitors using polynomial empirical scoring functions, Adv. Appl. Bioinforma. Chem. 7 (2014), pp. 1–9.
   PubMedGoogle Scholar
• F. Klepsch, P. Vasanthanathan, and G.F. Ecker, Ligand and structure-based classification models for prediction of P-glycoprotein inhibitors, J. Chem. Inf. Model. 54 (2013), pp. 218–229.
   Web of Science ®Google Scholar
• H. Sun, A naive Bayes classifier for prediction of multidrug resistance reversal activity on the basis of atom typing, J. Med. Chem. 48 (2005), pp. 4031–4039.
   PubMed Web of Science ®Google Scholar
• Y.H. Wang, Y. Li, S.L. Yang, and L. Yang, Classification of substrates and inhibitors of P-glycoprotein using unsupervised machine learning approach, J. Chem. Inf. Model. 45 (2005), pp. 750–757.
   PubMed Web of Science ®Google Scholar
• P. Crivori, B. Reinach, D. Pezzetta, and I. Poggesi, Computational models for identifying potential P-glycoprotein substrates and inhibitors, Mol. Pharm. 3 (2006), pp. 33–44.
   PubMed Web of Science ®Google Scholar
• S. Rapposelli, A. Coi, M. Imbriani, and A.M. Bianucci, Development of classification models for identifying "true" P-glycoprotein (P-gp) inhibitors through inhibition, ATPase activation and monolayer efflux assays, Int. J. Mol. Sci. 13 (2012), pp. 6924–6943.
   PubMed Web of Science ®Google Scholar
• S. Éric, M. Kalinic, K. Ilic, and M. Zloh, Computational classification models for predicting the interaction of drugs with P-glycoprotein and breast cancer resistance protein, SAR QSAR Environ. Res. 25 (2014), pp. 939–966.
   Web of Science ®Google Scholar
• K.M. Thai, N.T. Huynh, T.D. Ngo, T.T. Mai, T.H. Nguyen, and T.D. Tran, Three- and four-class classification models for P-glycoprotein inhibitors using counter-propagation neural networks, SAR QSAR Environ. Res. 26 (2015), pp. 139–163.
   PubMed Web of Science ®Google Scholar
• K.M. Thai, T.D. Ngo, T.V. Phan, T.D. Tran, N.V. Nguyen, T.H. Nguyen, and M.T. Le, Virtual screening for novel Staphylococcus aureus NorA efflux pump inhibitors from natural products, Med. Chem. 11 (2015), pp. 135–155.
   PubMed Web of Science ®Google Scholar
• R.J. Ferreira, D.J. dos Santos, M.J. Ferreira, and R.C. Guedes, Toward a better pharmacophore description of P-glycoprotein modulators, based on macrocyclic diterpenes from Euphorbia species, J. Chem. Inf. Model. 51 (2011), pp. 1315–1324.
   PubMed Web of Science ®Google Scholar
• I.K. Pajeva and M. Wiese, Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: Explanation of structural variety (hypothesis), J. Med. Chem. 45 (2002), pp. 5671–5686.
   PubMed Web of Science ®Google Scholar
• S. Ekins, R.B. Kim, B.F. Leake, A.H. Dantzig, E.G. Schuetz, L.B. Lan, K. Yasuda, R.L. Shepard, M.A. Winter, J.D. Schuetz, J.H. Wikel, and S.A. Wrighton, Three-dimensional quantitative structure–activity relationships of inhibitors of P-glycoprotein, Mol. Pharmacol. 61 (2002), pp. 964–973.
   PubMed Web of Science ®Google Scholar
• S. Ekins, R.B. Kim, B.F. Leake, A.H. Dantzig, E.G. Schuetz, L.B. Lan, K. Yasuda, R.L. Shepard, M.A. Winter, J.D. Schuetz, J.H. Wikel, and S.A. Wrighton, Application of three-dimensional quantitative structure–activity relationships of P-glycoprotein inhibitors and substrates, Mol. Pharmacol. 61 (2002), pp. 974–981.
   PubMed Web of Science ®Google Scholar
• A. Garrigues, N. Loiseau, M. Delaforge, J. Ferte, M. Garrigos, F. Andre, and S. Orlowski, Characterization of two pharmacophores on the multidrug transporter P-glycoprotein, Mol. Pharmacol. 62 (2002), pp. 1288–1298.
   PubMed Web of Science ®Google Scholar
• T. Langer, M. Eder, R.D. Hoffmann, P. Chiba, and G.F. Ecker, Lead identification for modulators of multidrug resistance based on in silico screening with a pharmacophoric feature model, Arch. Pharm. (Weinheim) 337 (2004), pp. 317–327.
   PubMed Web of Science ®Google Scholar
• F. Cortes-Selva, M. Campillo, C.P. Reyes, I.A. Jimenez, S. Castanys, I.L. Bazzocchi, L. Pardo, F. Gamarro, and A.G. Ravelo, SAR studies of dihydro-beta-agarofuran sesquiterpenes as inhibitors of the multidrug-resistance phenotype in a Leishmania tropica line overexpressing a P-glycoprotein-like transporter, J. Med. Chem. 47 (2004), pp. 576–587.
   PubMed Web of Science ®Google Scholar
• I. Pajeva, C. Globisch, R. Fleischer, I. Tsakovska, and M. Wiese, Molecular modeling of P-glycoprotein and related drugs, Med. Chem. Res. 14 (2005), pp. 106–117.
   Web of Science ®Google Scholar
• C. Chang, P.M. Bahadduri, J.E. Polli, P.W. Swaan, and S. Ekins, Rapid identification of P-glycoprotein substrates and inhibitors, Drug Metab. Dispos. 34 (2006), pp. 1976–1984.
   PubMed Web of Science ®Google Scholar
• C.P. Reyes, F. Munoz-Martinez, I.R. Torrecillas, C.R. Mendoza, F. Gamarro, I.L. Bazzocchi, M.J. Nunez, L. Pardo, S. Castanys, M. Campillo, and I.A. Jimenez, Biological evaluation, structure–activity relationships, and three-dimensional quantitative structure-activity relationship studies of dihydro-beta-agarofuran sesquiterpenes as modulators of P-glycoprotein-dependent multidrug resistance, J. Med. Chem. 50 (2007), pp. 4808–4817.
   PubMed Web of Science ®Google Scholar
• H. Zhou, S. Wu, S. Zhai, A. Liu, Y. Sun, R. Li, Y. Zhang, S. Ekins, P.W. Swaan, B. Fang, B. Zhang, and B. Yan, Design, synthesis, cytoselective toxicity, structure–activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells, J. Med. Chem. 51 (2008), pp. 1242–1251.
   PubMed Web of Science ®Google Scholar
• I.K. Pajeva, C. Globisch, and M. Wiese, Combined pharmacophore modeling, docking, and 3D QSAR studies of ABCB1 and ABCC1 transporter inhibitors, ChemMedChem 4 (2009), pp. 1883–1896.
   PubMed Web of Science ®Google Scholar
• A. Palmeira, F. Rodrigues, E. Sousa, M. Pinto, M.H. Vasconcelos, and M. Fernandes, Pharmacophore-based screening as a clue for the discovery of new p-glycoprotein inhibitors, in Advances in Bioinformatics, M. Rocha, F. Riverola, H. Shatkay, and J. Corchado, eds., Springer, Berlin, 2010, pp. 175–180.
   Google Scholar
• A. Palmeira, F. Rodrigues, E. Sousa, M. Pinto, M.H. Vasconcelos, and M.X. Fernandes, New uses for old drugs: Pharmacophore-based screening for the discovery of P-glycoprotein inhibitors, Chem. Biol. Drug Des. 78 (2011), pp. 57–72.
   PubMed Web of Science ®Google Scholar
• M.K. Leong, H.B. Chen, and Y.H. Shih, Prediction of promiscuous p-glycoprotein inhibition using a novel machine learning scheme, PLoS One 7 (2012), p. e33829.
   PubMedGoogle Scholar
• T. Dupree, Pharmacophore development and validation for inhibitors of the bacterial NorA efflux pump, Master of Science (Research) thesis, University of Wollongong, 2005.
   Google Scholar
• C. Wandel, R.B. Kim, S. Kajiji, P. Guengerich, G.R. Wilkinson, and A.J. Wood, P-glycoprotein and cytochrome P-450 3A inhibition: Dissociation of inhibitory potencies, Cancer Res. 59 (1999), pp. 3944–3948.
   PubMed Web of Science ®Google Scholar
• K. Yasuda, L.B. Lan, D. Sanglard, K. Furuya, J.D. Schuetz, and E.G. Schuetz, Interaction of cytochrome P450 3A inhibitors with P-glycoprotein, J. Pharmacol. Exp. Ther. 303 (2002), pp. 323–332.
   PubMed Web of Science ®Google Scholar